Table 1.

New pharmacological agents approved for genetic obesity.

	Drug Class	Dose	Route	Approved for	Most Common Side Effects
Metreleptin	Recombinant analog of leptin	0.03 mg/kg	subcutaneous	LEP deficiency	production of anti-leptin antibodies, increased risk of lymphomas
Setmelanotide	MC4R agonist	Max 3 mg	subcutaneous	POMC deficiency PCSK1 deficiency LEPR deficiency BBS	hyperpigmentation, nausea, vomiting, and injection site reactions
Semaglutide	GLP-1 receptor agonist	2.4 mg	subcutaneous	chronic weight management BMI ≥ 27 kg/m2, at least one weight-related ailment or BMI of ≥30 kg/m2. Age limit 12 years.	Nausea, vomiting, diarrhea, constipation
Liraglutide	GLP-1 receptor agonist	3 mg	subcutaneous	chronic weight management among pediatric patients aged ≥ 12 who are obese	nausea, vomiting, diarrhea, dizziness fever
Tirzepatide	GIP receptor and GLP-1 receptor agonist	2.5 mg	subcutaneous	chronic weight management BMI ≥ 27 kg/m2, at least one weight-related ailment or BMI of ≥30 kg/m2. It is only approved for adults.	nausea, diarrhea, vomiting, constipation, abdominal discomfort and pain, injection site reactions